Unmatched for Industry Firsts

The innovations of the members of Piedmont’s leadership team have transformed the field of companion animal veterinary medicine and resulted in a long list of industry firsts:

• First and only single treatment topical for otitis externa in dogs [CLARO® (florfenicol, terbinafine, mometasone furoate)]
• First soft-chew medicinal platform with three global patents [QUELLIN™ (carprofen)]
• First oral once-a-month flea control for dogs and cats [PROGRAM® (lufenuron)]
• First to reach $175 million in sales for a companion animal product [PROGRAM® Tablets]
• First TV campaign supporting an FDA veterinary prescription product [PROGRAM®]
• First six-month injectable for flea control in cats [PROGRAM® 6-month injectable]
• First combination oral product for flea and heartworm control [SENTINEL® (milbemycin oxime/lufenuron)]

• First FDA approval of an oral adulticidal flea control [CAPSTAR® (nitenpyram)]
• First water-based formulation of ivermectin [ACAREXX® (ivermectin)]
• First and only treatment for Addison’s disease in dogs approved by FDA [PERCORTEN-V® (DOCP)]
• First and only insulin for cats approved by FDA and only recombinant insulin approved in animal health [PROZINC® (protamine zinc recombinant human insulin)]
• First EPA biopesticide registration for companion animals [RESULTIX®]
• First topical NSAID product for horses [SURPASS® (1% diclofenac sodium)]
• First feed-through fly control for horses
  [SOLITUDE IGR®]
• First and only oral imidacloprid product [ADVANTUS® (imidacloprid)]